相关实验视频

Updated: Jul 1, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

通过对UBASH3A和UBASH3B表达的对立作用,FLI1诱导了红血球白血病

Jie Wang^1,2, Chunlin Wang^1,2, Anling Hu^1,2

¹State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang-550014, Guizhou, People's Republic of China.

|March 9, 2024

概括

通过调节UBASH3B和UBASH3A,FLI1促进红血球白血病. UBASH3B充当瘤基因,而UBASH3A充当瘤抑制剂,影响疾病的进展.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因规则基因规则

背景情况:

FLI1是一种瘤转录因子,与各种恶性瘤有关.
FLI1驱动癌症的确切机制尚未完全阐明.
研究了FLI1在调节Ubiquitin关联和SH3域含有A/B (UBASH3A/B) 基因中的作用.

研究的目的:

阐明UBASH3B和UBASH3A在红血球白血病中的功能性作用.
要确定FLI1如何调节UBASH3A/B的表达.
为了确定FLI1驱动的红血球白血病的治疗点.

主要方法:

促进体分析,化酶测定和ChIP用于研究UBASH3A/B基因调节.
RNAseq和生物信息学,以评估UBASH3A/B淘汰的影响.
使用shRNA和小分子抑制剂抑制下游目标.
西部涂抹,RT-qPCR,MTT测定和流细胞计,以评估分子和细胞效应.

主要成果:

FLI1直接激活UBASH3B,促进白血病细胞的增殖和抑制AP1的表达.
FLI1通过GATA2间接抑制UBASH3A,从而对抗白血病的生长,并激活HSPA1B (HSP70).
UBASH3B的过度表达与预后不佳相关,而UBASH3A的过度表达与癌症的良好预后有关.

结论:

FLI1通过差异调节致癌性UBASH3B和瘤抑制剂UBASH3A来驱动红血球白血病.
UBASH3B和UBASH3A代表了FLI1介导恶性瘤中的潜在治疗点.
了解FLI1,UBASH3A/B及其下游效应器之间的相互作用对于癌症治疗至关重要.

关键词:

AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 AP1 FLI1 FLI1 的意思是什么?在HSPA1B中,它是HSPA1B.白血病的扩散白血病的扩散在瘤基因上,我们发现了瘤基因.这就是SYK.转录法规转录法规瘤抑制剂是一种瘤抑制剂.这就是UBASH3A.这就是UBASH3B.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Regulation of the Unfolded Protein Response

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...